William G Kaelin

List of Publications by Year
in descending order

112 papers	25,837 citations	20036 63 h-index	30277 107 g-index
155 all docs	155 docs citations	155 times ranked	34731 citing authors

#	Article	IF	Citations
1	Sensitivity of<i>VHL</i>mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120403119.	3.3	11
2	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	3.2	12
3	A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer. Clinical Cancer Research, 2022, 28, 4689-4701.	3.2	5
4	Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Research, 2021, 31, 80-93.	5.7	51
5	Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances, 2021, 7, .	4.7	26
6	DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. Neuro-Oncology Advances, 2021, 3, i12-i13.	0.4	1
7	Belzutifan, a Potent HIF2Î± Inhibitor, in the Pacakâ€“Zhuang Syndrome. New England Journal of Medicine, 2021, 385, 2059-2065.	13.9	36
8	David M. Livingston (1941â€“2021). Cell, 2021, 184, 6007-6009.	13.5	1
9	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9.	7.7	138
10	Leveraging insights into cancer metabolismâ€”a symposium report. Annals of the New York Academy of Sciences, 2020, 1462, 5-13.	1.8	3
11	2-Oxoglutarate-dependent dioxygenases in cancer. Nature Reviews Cancer, 2020, 20, 710-726.	12.8	119
12	Targeting the HIF2â€“VEGF axis in renal cell carcinoma. Nature Medicine, 2020, 26, 1519-1530.	15.2	248
13	Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders. Blood, 2020, 136, 13-14.	0.6	0
14	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes and Development, 2019, 33, 1718-1738.	2.7	65
15	HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Science Signaling, 2019, 12, .	1.6	47
16	Peptidic degron for IMiD-induced degradation of heterologous proteins. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2539-2544.	3.3	41
17	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science, 2019, 363, 1217-1222.	6.0	281
18	Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metabolism, 2019, 29, 1166-1181.e6.	7.2	121

#	Article	IF	Citations
19	EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16997-17006.	3.3	13
20	Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discovery, 2019, 9, 230-247.	7.7	119
21	Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. JCI Insight, 2019, 4, .	2.3	21
22	The von Hippelâ€“Lindau Tumor Suppressor Protein. Annual Review of Cancer Biology, 2018, 2, 91-109.	2.3	13
23	Senator McCain and Our Shared Humanity. American Journal of Medicine, 2018, 131, 216-217.	0.6	0
24	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898
25	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3741-E3748.	3.3	10
26	HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. Journal of Clinical Oncology, 2018, 36, 908-910.	0.8	14
27	BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1Î± activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9600-E9609.	3.3	20
28	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell, 2018, 175, 101-116.e25.	13.5	234
29	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	6.0	134
30	Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL ^{âˆ’/âˆ’} clear cell renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1027-1032.	3.3	126
31	The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks. Molecular Cell, 2017, 66, 772-779.	4.5	192
32	Common pitfalls in preclinical cancer target validation. Nature Reviews Cancer, 2017, 17, 441-450.	12.8	134
33	HIF activation causes synthetic lethality between the <i>VHL</i> tumor suppressor and the <i>EZH1</i> histone methyltransferase. Science Translational Medicine, 2017, 9, .	5.8	36
34	Climate Change. JAMA - Journal of the American Medical Association, 2017, 318, 611.	3.8	2
35	The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. Transactions of the American Clinical and Climatological Association, 2017, 128, 298-307.	0.9	70
36	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. Cell, 2016, 166, 126-139.	13.5	187

#	Article	IF	Citations
37	Targeting HIF2 in Clear Cell Renal Cell Carcinoma. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 113-121.	2.0	43
38	On-target efficacy of a HIF-2Î± antagonist in preclinical kidney cancer models. Nature, 2016, 539, 107-111.	13.7	341
39	pVHL suppresses kinase activity of Akt in a proline-hydroxylationâ€“dependent manner. Science, 2016, 353, 929-932.	6.0	165
40	PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2. Molecular Cell, 2016, 63, 1006-1020.	4.5	120
41	Pathways for Oxygen Regulation and Homeostasis. JAMA - Journal of the American Medical Association, 2016, 316, 1252.	3.8	36
42	EGLN1 Inhibition and Rerouting of Î±-Ketoglutarate Suffice for Remote Ischemic Protection. Cell, 2016, 164, 884-895.	13.5	108
43	Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. Journal of Biological Chemistry, 2016, 291, 4256-4265.	1.6	234
44	EglN2 associates with the <scp>NRF</scp>1â€‹<scp>PGC</scp>1Î± complex and controls mitochondrial function in breastÂcancer. EMBO Journal, 2015, 34, 2953-2970.	3.5	58
45	Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15372-15377.	3.3	24
46	Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11642-11647.	3.3	46
47	Molecular Biology of Kidney Cancer. , 2015, , 31-57.		10
48	DisABLing Kidney Cancers Caused by Fumarate Hydratase Mutations. Cancer Cell, 2014, 26, 779-780.	7.7	2
49	Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis. Cancer Research, 2014, 74, 6554-6564.	0.4	32
50	The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science, 2014, 343, 305-309.	6.0	1,196
51	Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes and Development, 2014, 28, 1429-1444.	2.7	111
52	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell, 2014, 26, 222-234.	7.7	71
53	A genetic mechanism for Tibetan high-altitude adaptation. Nature Genetics, 2014, 46, 951-956.	9.4	322
54	A Comprehensive Study of the VHL-R200W Chuvash Polycythemia Mutation Reveals a Gradual Dysregulation of the Hypoxia Pathway in Oncogenesis. Blood, 2014, 124, 4020-4020.	0.6	1

#	Article	IF	Citations
55	IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia. Blood, 2014, 124, SCI-6-SCI-6.	0.6	1
56	Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents. Blood, 2014, 124, 420-420.	0.6	0
57	(<i>R</i>)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. Science, 2013, 339, 1621-1625.	6.0	624
58	SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. Cancer Cell, 2013, 24, 738-750.	7.7	135
59	Influence of Metabolism on Epigenetics and Disease. Cell, 2013, 153, 56-69.	13.5	729
60	What a difference a hydroxyl makes: mutant IDH, (<i>R</i>)-2-hydroxyglutarate, and cancer. Genes and Development, 2013, 27, 836-852.	2.7	491
61	Use and Abuse of RNAi to Study Mammalian Gene Function. Science, 2012, 337, 421-422.	6.0	158
62	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 2012, 483, 484-488.	13.7	630
63	Transformation by Mutant IDH and (R)-2HG Is Reversible.. Blood, 2012, 120, 2413-2413.	0.6	0
64	Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes. Blood, 2012, 120, 3509-3509.	0.6	1
65	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	9.4	270
66	Genetic and Functional Studies Implicate <i>HIF1</i>Î± as a 14q Kidney Cancer Suppressor Gene. Cancer Discovery, 2011, 1, 222-235.	7.7	347
67	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking <i>Rb1</i> or <i>Men1</i>. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13379-13386.	3.3	143
68	Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis,. Blood, 2011, 118, 3161-3161.	0.6	1
69	Enantiomer-Specific Transformation by 2HG Is Linked to Opposing Effects on Î±-Ketoglutarate-Dependent Dioxygenases. Blood, 2011, 118, LBA-4-LBA-4.	0.6	1
70	Enantiomer-Specific Transformation by 2HG Is Linked to Opposing Effects on Î±-Ketoglutarate-Dependent Dioxygenases. Blood, 2011, 118, LBA-4-LBA-4.	0.6	0
71	New cancer targets emerging from studies of the Von Hippelâ€Lindau tumor suppressor protein. Annals of the New York Academy of Sciences, 2010, 1210, 1-7.	1.8	11
72	SDH5 Mutations and Familial Paraganglioma: Somewhere Warburg is Smiling. Cancer Cell, 2009, 16, 180-182.	7.7	58

#	Article	IF	Citations
73	Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase. Cancer Cell, 2009, 16, 413-424.	7.7	120
74	Treatment of kidney cancer. Cancer, 2009, 115, 2262-2272.	2.0	105
75	Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Medicine, 2009, 1, 99.	3.6	77
76	The von Hippelâ€"Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews Cancer, 2008, 8, 865-873.	12.8	616
77	Kidney Cancer: Now Available in a New Flavor. Cancer Cell, 2008, 14, 423-424.	7.7	31
78	Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway. Molecular Cell, 2008, 30, 393-402.	4.5	2,614
79	Kinase requirements in human cells: III. Altered kinase requirements in<i>VHL</i>â^’/â^’ cancer cells detected in a pilot synthetic lethal screen. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16484-16489.	3.3	137
80	The von Hippelâ€Lindau Tumor Suppressor Protein: An Update. Methods in Enzymology, 2007, 435, 371-383.	0.4	42
81	The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma: Fig. 1.. Clinical Cancer Research, 2007, 13, 680s-684s.	3.2	275
82	Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations. Molecular and Cellular Biology, 2007, 27, 5381-5392.	1.1	102
83	The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase. Cell, 2007, 128, 889-900.	13.5	399
84	pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-Î°B Agonist Card9 by CK2. Molecular Cell, 2007, 28, 15-27.	4.5	163
85	von Hippel-Lindau Disease. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 145-173.	9.6	293
86	Failure to prolyl hydroxylate hypoxia-inducible factor Î± phenocopies VHL inactivation in vivo. EMBO Journal, 2006, 25, 4650-4662.	3.5	210
87	Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 105-110.	3.3	274
88	The Concept of Synthetic Lethality in the Context of Anticancer Therapy. Nature Reviews Cancer, 2005, 5, 689-698.	12.8	1,278
89	Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell, 2005, 8, 155-167.	7.7	494
90	Binding of pRB to the PHD Protein RBP2 Promotes Cellular Differentiation. Molecular Cell, 2005, 18, 623-635.	4.5	215

#	Article	IF	Citations
91	The von Hippelâ€"Lindau protein, HIF hydroxylation, and oxygen sensing. Biochemical and Biophysical Research Communications, 2005, 338, 627-638.	1.0	197
92	ROS: Really involved in Oxygen Sensing. Cell Metabolism, 2005, 1, 357-358.	7.2	150
93	PROLINE HYDROXYLATION AND GENE EXPRESSION. Annual Review of Biochemistry, 2005, 74, 115-128.	5.0	410
94	Analysis of von Hippelâ€"Lindau Hereditary Cancer Syndrome: Implications of Oxygen Sensing. Methods in Enzymology, 2004, 381, 320-335.	0.4	9
95	Gleevec: Prototype or Outlier?. Science Signaling, 2004, 2004, pe12-pe12.	1.6	19
96	The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Fig. 1.. Clinical Cancer Research, 2004, 10, 6290S-6295S.	3.2	268
97	The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing. Journal of the American Society of Nephrology: JASN, 2003, 14, 2703-2711.	3.0	115
98	Inhibition of HIF2Î± Is Sufficient to Suppress pVHL-Defective Tumor Growth. PLoS Biology, 2003, 1, e83.	2.6	516
99	Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that have Undergone Cre-Mediated Recombination. Molecular Imaging, 2003, 2, 153535002003031.	0.7	36
100	How oxygen makes its presence felt. Genes and Development, 2002, 16, 1441-1445.	2.7	138
101	Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 2002, 1, 237-246.	7.7	695
102	Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer, 2002, 2, 673-682.	12.8	767
103	Structure of an HIF-1alpha -pVHL Complex: Hydroxyproline Recognition in Signaling. Science, 2002, 296, 1886-1889.	6.0	679
104	Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene, 2000, 19, 5703-5711.	2.6	21
105	Ubiquitination of hypoxia-inducible factor requires direct binding to the Î²-domain of the von Hippelâ€"Lindau protein. Nature Cell Biology, 2000, 2, 423-427.	4.6	1,423
106	A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature, 2000, 407, 642-645.	13.7	309
107	Many vessels, faulty gene. Nature, 1999, 399, 203-204.	13.7	47
108	The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature, 1999, 399, 806-809.	13.7	863

#	Article	IF	Citations
109	The p53 gene family. Oncogene, 1999, 18, 7701-7705.	2.6	175
110	Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function. Science, 1999, 284, 455-461.	6.0	793
111	Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Medicine, 1997, 3, 1145-1149.	15.2	158
112	Tumour suppression by the human von Hippel-Lindau gene product. Nature Medicine, 1995, 1, 822-826.	15.2	636